Are lecanemab and donanemab disease-modifying therapies?

Alzheimers Dement · 2024 · PMC11497653 · PMID 39096161

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Indeed, these trials dramatically reduced brain Aβ‐positron emission tomography (PET) burden and demonstrated a highly significant, albeit clinically modest, delay of cognitive decline.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.